文献速递脑血管病

降压药用于缺血性卒中或短暂性脑缺血发作后二级预防:系统综述与荟萃分析

Antihypertensive Drugs for Secondary Prevention After Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.
PubMed 文献 · Stroke · 2021-04-27

中等质量证据显示,与安慰剂相比,任何类型降压药使后续卒中风险从9.7%降至7.9%(OR 0.79,95%CI 0.66-0.94),绝对风险降低1.9%;全因死亡率无显著差异(7.3% vs 7.9%,OR 1.01,95%CI 0.92-1.10)。

要点

  • 降压药使缺血性卒中/TIA后后续卒中绝对风险降低1.9%。
  • 全因死亡率与安慰剂组无显著差异(OR 1.01)。
  • 证据质量中等,支持多数患者使用降压药二级预防。

核心结论

  • 缺血性卒中或TIA患者使用降压药与卒中风险降低1.9%相关,但不影响全因死亡风险。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、EMBASE和Cochrane Central Register of Controlled Trials至2020年1月31日。
  • 比较任何特定降压药(单药或联合)与对照或另一种降压药。

主要发现

  • 后续卒中发生于7.9%的降压药组患者(缺血性7.4%,出血性0.6%),安慰剂组为9.7%(OR 0.79,95%CI 0.66-0.94;绝对风险差-1.9%,95%CI -3.1%至-0.5%)。
  • 全因死亡绝对风险降压药组7.3%,安慰剂组7.9%(OR 1.01,95%CI 0.92-1.10;绝对风险差0.1%,95%CI -0.6%至0.7%)。

关键数值与推荐

  • 后续卒中风险降低:OR 0.79(95%CI 0.66-0.94),绝对风险差-1.9%(95%CI -3.1%至-0.5%)。
  • 全因死亡风险:OR 1.01(95%CI 0.92-1.10),绝对风险差0.1%(95%CI -0.6%至0.7%)。

临床怎么用

  • 对于缺血性卒中或TIA患者,可考虑使用降压药进行二级预防以降低后续卒中风险。
  • 降压治疗对全因死亡率无明显影响,决策时应结合患者个体情况。

局限性

  • 证据质量中等,部分结果可能存在异质性或不精确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Approximately 30% of ischemic strokes occur after a previous stroke or transient ischemic attack. Arterial hypertension is one of the best established risk factors for first and recurrent stroke, both ischemic and hemorrhagic. Guidelines for the secondary prevention of ischemic stroke support the use of blood pressure (BP)-lowering drugs in most patients. However, the evidence for these recommendations comes from meta-analyses that included both ischemic and hemorrhagic stroke patients, whereas these 2 conditions differ quantitatively in several aspects. With this systematic review and meta-analysis, we aimed at summarizing the current evidence on BP-lowering drugs for secondary prevention in patients with ischemic stroke or transient ischemic attack. METHODS: We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials up to January 31, 2020. We included randomized controlled trials comparing any specific BP-lowering drug, as monotherapy or combination, with either a control or another BP-lowering drug. RESULTS: Eight studies that enrolled 33 774 patients with ischemic stroke or transient ischemic attack were included in the meta-analysis. Mean follow-up was 25 months (range, 3-48). Moderate-quality evidence indicated that a subsequent stroke occurred in 7.9% (ischemic in 7.4% or hemorrhagic in 0.6%) of patients taking any type of BP-lowering drug compared with 9.7% of patients taking placebo (odds ratio, 0.79 [95% CI, 0.66-0.94]; absolute risk difference, -1.9% [95% CI, -3.1% to -0.5%]). Moderate-quality evidence indicated that mortality occurred similarly in patients taking any type of BP-lowering treatment compared with placebo, with an absolute risk of 7.3% and 7.9%, respectively (odds ratio, 1.01 [95% CI, 0.92-1.10]; absolute risk difference, 0.1% [95% CI, -0.6% to 0.7%]). CONCLUSIONS: The use of BP-lowering drugs in patients with ischemic stroke or transient ischemic attack is associated with a 1.9% risk reduction of stroke but does not affect the all-cause mortality risk.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Boncoraglio GB, Del Giovane C, Tramacere I, et al. Antihypertensive Drugs for Secondary Prevention After Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis. Stroke. 2021. PMID: 33902303. doi:10.1161/STROKEAHA.120.031945

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。